Influence of 2-( 18F) fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography on recurrent ovarian cancer diagnosis and on selection of patients for secondary cytoreductive surgery

International Journal of Gynecological Cancer

Volumn 19, Issue 4, 2009, Pages 600-604

  Risum, Signe ^a   Høgdall, Claus ^b   Markova, Elena ^c   Berthelsen, Anne K ^c   Loft, Annika ^c   Jensen, Flemming ^b   Høgdall, Estrid ^d   Roed, Henrik ^a   Engelholm, Svend A ^a  

^a FINSEN LABORATORY   (Denmark)

^b Rigshospitalet   (Denmark)

^c Center of Diagnostic Investigations   (Denmark)

^d INSTITUTE OF CANCER EPIDEMIOLOGY   (Denmark)

Author keywords

CA125; Diagnostics; Positron emission tomography; Recurrent ovarian cancer; Secondary cytoreductive surgery

Indexed keywords

CA 125 ANTIGEN; FLUORODEOXYGLUCOSE F 18; DIAGNOSTIC AGENT; RADIOPHARMACEUTICAL AGENT;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER REGRESSION; CLINICAL TRIAL; COMPARATIVE STUDY; COMPUTER ASSISTED EMISSION TOMOGRAPHY; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOREDUCTIVE SURGERY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; OVARY CANCER; PATIENT REFERRAL; PATIENT SELECTION; PHYSICAL EXAMINATION; PRIORITY JOURNAL; PROSPECTIVE STUDY; RECURRENT CANCER; SENSITIVITY AND SPECIFICITY; TRANSVAGINAL ECHOGRAPHY; ECHOGRAPHY; METHODOLOGY; MIDDLE AGED; OVARY TUMOR; POSITRON EMISSION TOMOGRAPHY; SCINTISCANNING; TUMOR RECURRENCE;

ADULT; AGED; AGED, 80 AND OVER; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; OVARIAN NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY; PROSPECTIVE STUDIES; RADIOPHARMACEUTICALS; SENSITIVITY AND SPECIFICITY; TOMOGRAPHY, X-RAY COMPUTED; YOUNG ADULT;

EID: 67651046267     PISSN: 1048891X     EISSN: None     Source Type: Journal    
DOI: 10.1111/IGC.0b013e3181a3cc94     Document Type: Article

References (33)

1. Rustin GJ, Nelstrop AE, Tuxen MK, et al. Defining progression of ovarian carcinoma during follow-up according to CA 125; a North Thames Ovary Group study. Ann Oncol. 1996;7:361-364.
2. Rustin GJ, Marples M, Nelstrop AE, et al. Use of CA-125 to define progression of ovarian cancer in patients with persistently elevated levels. J Clin Oncol. 2001;19:4054-4057.
3. Rustin GJ. Use of CA-125 to assess response to new agents in ovarian cancer trials. J Clin Oncol. 2003;21:187-193.
4. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92:205-216.
5. Goonewardene TI, Hall MR, Rustin GJ. Management of asymptomatic patients on follow-up for ovarian cancer with rising CA-125 concentrations. Lancet Oncol. 2007;8:813-821.
6. Santillan A, Garg R, Zahurak ML, et al. Risk of epithelial ovarian cancer recurrence in patients with rising serum CA125 levels within the normal range. J Clin Oncol. 2005;23:9338-9343.
7. Berek JS, Hacker NF, Lagasse LD, et al. Survival of patients following secondary cytoreductive surgery on ovarian cancer. Obstet Gynecol. 1983;61:189-193.
8. Güngör M, Ortaç F, Arvas M, et al. The role of secondary cytoreductive surgery for recurrent ovarian cancer. Gynecol Oncol. 2005;97:74-79.
9. Zang RY, Li ZT, Tang J, et al. Secondary cytoreductive surgery for patients with relapsed epithelial ovarian carcinoma: who benefits? Cancer. 2004;100:1152-1161.
10. Eisenkop SM, Friedman RL, Spirtos NM. The role of secondary cytoreductive surgery in the treatment of patients with recurrent epithelial ovarian carcinoma. Cancer. 2000;88:144-153.
11. Gadducci A, Iacconi P, Cosio S, et al. Complete salvage surgical cytoreduction improves further survival of patients with late recurrent ovarian cancer. Gynecol Oncol. 2000;79:344-349.
12. Gronlund B, Lundvall L, Christensen IJ, et al. Surgical cytoreduction in recurrent ovarian carcinoma in patients with complete response to paclitaxel-platinum. Eur J Surg Oncol. 2005;31:67-73.
13. Salani R, Santillan A, Zahurak ML, et al. Secondary cytoreductive surgery for localized, recurrent epithelial ovarian cancer: analysis of prognostic factors and survival outcome. Cancer. 2007;109:685-691.
14. Munkarah AR, Coleman RL. Critical evaluation of secondary cytoreduction in recurrent ovarian cancer. Gynecol Oncol. 2004;95:273-280.
15. Hauspy J, Covens A. Cytoreductive surgery for recurrent ovarian cancer. Curr Opin Obstet Gynecol. 2007;19:15-21.
16. Fadder AN, Rose PG. Role of surgery in ovarian carcinoma. J Clin Oncol. 2007;25:2873-2883.
17. Bristow RE, del Carmen MG, Pannu HK, et al. Clinically occult recurrent ovarian cancer: patient selection for secondary cytoreductive surgery using combined PET/CT. Gynecol Oncol. 2003;90:519-528.
18. Pannu HK, Cohade C, Bristow RE, et al. PET-CT detection of abdominal recurrence of ovarian cancer: radiologic-surgical correlation. Abdom Imaging. 2004;39:398-403.
19. Chung HH, Kang WJ, Kim JW, et al. Role of [18F]FDG PET/CT in the assessment of suspected recurrent ovarian cancer: correlation with clinical or histological findings. Eur J Nucl Med Mol Imaging. 2007;34:480-486.
20. Thrall MM, DeLoia JA, Gallion H, et al. Clinical use of combined positron emission tomography and computed tomography (FDG-PET/CT) in recurrent ovarian cancer. Gynecol Oncol. 2007;105:17-22.
21. Kim CK, Park BK, Choi JY, et al. Detection of recurrent ovarian cancer at MRI: comparison with integrated PET/CT. J Comput Assist Tomogr. 2007;31:868-875.
22. Gaducci A, Cosio S, Zola P, et al. Surveillance procedures for patients treated for epithelial ovarian cancer: a review of the literature. Int J Gynecol Cancer. 2007;17:21-31.
23. Grabiec M, Walentowicz M, Nowicki P. The value of FDG PET/CT, ultrasound, and CT in diagnosing recurrent ovarian carcinoma. Ginekol Pol. 2006;77:746-752.
24. Fehm T, Heller F, Krämer S, et al. Evaluation of CA125, physical, and radiological findings in follow-up of ovarian cancer patients. Anticancer Res. 2005;25:1551-1554.
25. Clarke-Pearson DL, Bandy LC, Dudzinski M, et al. Computed tomography in evaluation of patients with ovarian carcinoma in complete clinical remission. Correlation with surgical-pathologic findings. JAMA. 1986;255:627-630.
26. Silverman PM, Osborne M, Dunnick NR, et al. CT prior to second-look operation in ovarian cancer. AJR Am J Roentgenol. 1988;150:829-832.
27. Prayer L, Kainz C, Kramer J, et al. CT and MR accuracy in the detection of tumor recurrence in patients treated for ovarian cancer. J Comput Assist Tomogr. 1993;17:626-632.
28. De Rosa V, Mangoni de Stefano ML, Brunetti A, et al. Computed tomography and second-look surgery in ovarian cancer patients. Eur J Gynaecol Oncol. 1995;16:123-129.
29. Ferrozzi F, Bova D, De Chiara F, et al. Thin-section CT follow-up of metastatic ovarian carcinoma correlation with levels of CA-125 marker and clinical history. Clin Imaging. 1998;22:364-370.
30. Topuz E, Aydiner A, Saip P, et al. Correlations of serum CA125 level and computerized tomography (CT) imaging with laparotomic findings following intraperitoneal chemotherapy in patients with ovarian cancer. Eur J Gynaecol Oncol. 2000;21:599-602.
31. Martínez-Román S, Ramirez PT, Oh J, et al. Combined positron emission tomography and computed tomography for the detection of recurrent ovarian mucinous adenocarcinoma. Gynecol Oncol. 2005;96:888-891.
32. Berger KL, Nicholson SA, Dehdashti F, et al. FDG PET evaluation of mucinous neoplasms: correlation of FDG uptake with histopathologic features. AJR Am J Roentgenol. 2000;174:1005-1008.
33. Fung-Kee-Fung M, Oliver T, Elit L, et al. Optimal chemotherapy treatment for women with recurrent ovarian cancer. Curr Oncol. 2007;14:195-208.